Purified anti-human GM-CSF Antibody
- 产品名称:
- Purified anti-human GM-CSF Antibody
- 产品类别:
- 抗体
- 产品编号:
- 502201
- 产品应用:
- 502201
- Verified Reactivity
- Human
- Antibody Type
- Monoclonal
- Host Species
- Rat
- Immunogen
- E. coli -expressed, recombinant human GM-CSF
- Formulation
- Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
- Preparation
- The antibody was purified by affinity chromatography.
- Concentration
- 0.5 mg/ml
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C.
- Application
-
ELISA Capture - Quality tested
IP, WB - Reported in the literature, not verified in house
- Recommended Usage
Each lot of this antibody is quality control tested by ELISA assay. For ELISA capture applications, a concentration range of 2-6 ?g/ml is recommended. To obtain a linear standard curve, serial dilutions of GM-CSF recombinant protein ranging from 500 to 4 pg/ml are recommended for each ELISA plate. It is recommended that the reagent be titrated for optimal performance for each application.
- Application Notes
ELISA or ELISPOT Capture1-6: The Purified BVD2-23B6 antibody is useful as the capture antibody in a sandwich ELISA or ELISPOT assay, when used in conjunction with the biotinylated BVD2-21C11 antibody (Cat. No. 502304) as the detecting antibody. The Ultra-LEAF? Purified antibody is suggested for ELISPOT capture.
Neutralization1-4: The Ultra-LEAF? Purified antibody (Endotoxin <0.01 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for neutralization of human GM-CSF bioactivity (Cat. Nos. 502205 - 502210).
Additional reported applications (for the relevant formats) include: immunoprecipitation3 and Western blotting.
Note: For testing human GM-CSF in serum or plasma, BioLegend's ELISA Max? Sets (Cat. Nos. 432001 and 432004) are specially developed and recommended.
- Application References
(PubMed link indicates BioLegend citation) -
- Bacchetta R, et al. 1990. J. Immunol. 144:902.
- Kita H, et al. 1991. J. Exp. Med. 174:745.
- Abrams J, et al. 1992. Immunol. Rev. 127:5.
- Abrams J, et al. 1994. Eosinophils in Allergy and Inflammation. Marcel Dekker New York. p.133.
- Mahanty S, et al. 1992. J. Immunol. 148:3567.
- Klinman D, et al. 1994. Curr. Prot. Immunol.. John Wiley and Sons New York. Unit 6.19.
- Product Citations
-
- Takeuchi S, et al. 2015. Cancer Res . 75: 2629 - 2640. PubMed
- RRID
- AB_315211 (BioLegend Cat. No. 502201) AB_315212 (BioLegend Cat. No. 502202)
- Structure
- Cytokine; 22 kD (Mammalian)
- Bioactivity
- Growth/development granulocyte/macrophage progenitors; differentiates myeloblasts/monoblasts; synergizes with Epo proliferation of erythroid/megakaryocytic progenitors
- Cell Sources
- T cells, macrophages, fibroblasts, endothelial cells, mast cells
- Cell Targets
- Granulocyte/macrophage/erythroid/megakaryocytic progenitors, myeloblasts, monoblasts
- Receptors
- Heterodimer GM-CSFR α subunit (CDw116); β-subunit (CDw131) which is also shared the IL-3 and IL-5 receptor α chains
- Biology Area
- Cell Biology, Stem Cells
- Molecular Family
- Cytokines/Chemokines, Growth Factors
- Antigen References
-
1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press San Diego.
2. Demetri G, et al. 1991. Blood 78:2791.
3. Fan D, et al. 1991. In vivo 5:571.
4. Negrin R, et al. 1992. Adv. Pharmacol. 23:263.
- Regulation
- Synergistic with IL-1, IL-3, G-CSF; E21R competitive antagonist for receptor binding; stored in ECM with heparan sulfate proteoglycans
- Gene ID
- 1437 View all products for this Gene ID
- UniProt
- View information about GM-CSF on UniProt.org